Kornimate/medical-research-clean huggingface dataset:
effects of proprioceptive training with routine pt on gross motor function in spastic quadriplegic cp

Conditions: Cerebral Palsy

Summary: the proprioceptive training with a therapy regime enhances the body's somatosensory input that in result changes the body to be more functional in different types of interactions. this study is dedicated to finding out how much proprioception training is helpful in gross motor function level improvement and enhances functional activities of cp children

proprioception plays an important role in the correct execution of efferent motor performance as 70% of cerebral palsy population have deficit in receiving somatosensory signals3. tradition physical therapy exercises including strengthening followed by stretching etc. should be reviewed and the therapy must be more oriented to overall individual growth and development31. there is a need to push the cerebral palsy population to be exercised with proprioceptive stimulation for their maximum participation in the activities of daily life including both personal and social aspects. the proprioceptive training with a therapy regime enhances the body's somatosensory input that in result changes the body to be more functional in different types of interactions. this study is dedicated to finding out how much proprioception training is helpful in gross motor function level improvement and enhances functional activities of cp children.

Eligibility criteria:
inclusion criteria: * children with the diagnosis of cerebral palsy (spastic quadriplegia) * ages of 1 to 5 years * both males and females * alert and responsive to verbal and non-verbal commands * modified ashworth sale grade 1 to 2 * gross motor function classification system level 1v and v exclusion criteria: * children under the botox treatment for tone management (botulinum injections) * diagnosed with any disease other than spastic quadriplegic cerebral palsy i.e. congenital heart defects, epilepsy, recurrent pneumonia, skin infections etc. * children underwent any surgery i.e. tenotomy (tendon release), recent heart surgery, * recent fracture and subluxation/dislocation due to fall or poor handling * any contracture or deformity on upper extremities, lower extremities and spine i.e. flexion contractures, club foot, scoliosis

Keywords: : spastic quadriplegia, cerebral palsy proprioceptive training, somatosensory input
an extension study to evaluate safety and efficacy of bmn 111 in children with achondroplasia

Conditions: Achondroplasia

Summary: this is a phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of bmn111 in children with achondroplasia until subjects reach near-adult final height. eligible subjects will have completed 1 year of bmn111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of bmn111 by subcutaneous injection according to their age as determined by 111-206.


Eligibility criteria:
inclusion criteria: 1. must have completed study 111-206 on investigational treatment (bmn 111 or placebo). 2. parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research related procedure. also, subjects under the age of majority are willing and able to provide written assent (if required by local regulations or the irb/iec) after the nature of the study has been explained and prior to performance of any research-related procedure. subjects who reach the age of majority in their country while the study is ongoing will be asked to provide their own written consent again upon reaching the legal age of majority. 3. are willing and able to perform all study procedures exclusion criteria: 1. permanently discontinued bmn 111 or placebo prior to completion of study 111-206 2. have a clinically significant finding or arrhythmia on ecg that indicates abnormal cardiac function or conduction or qtc-f \> 450 msec 3. require any investigational agent (except bmn 111) prior to completion of study period 4. current therapy with antihypertensive medications, angiotensin-converting enzyme (ace) inhibitors, angiotensin ii receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, gnrh agonists, any medication that may impair or enhance compensatory tachycardia, diuretics, or other drugs known to alter renal or tubular function 5. pregnant or planning to become pregnant (self or partner) at any time during the study 6. concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason 7. have a condition or circumstance that, in the view of the investigator, places the subject at high risk for poor treatment compliance

Keywords: dwarfism bone disease ach natriuretic peptide c-type musculoskeletal diseases skeletal dysplasias
angiogenic biomarkers in juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis (JIA)

Summary: the aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, ccn1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

juvenile idiopathic arthritis (jia) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. the most common pediatric rheumatologic disease. jia is the most common pediatric rheumatologic disease. apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of jia, especially polyarticular jia, has been identified. the team has been interested in the prognosis of ra for many years. thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of ra patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and ccn1 protein. this has been demonstrated in vitro but also in vivo from sera of ra patients. these markers are associated with activity and structural damage in ra. the project aims to study the interest of these same angiogenic biomarkers in the serum of jia patients in order to establish whether, as in ra, they are also associated with disease severity.

Eligibility criteria:
inclusion criteria: * greater than or equal to 16 years-old * diagnosis of juvenile idiopathic arthritis with specialized follow up in rheumatology at cochin hospital * no-opposition to the research * patient with health insurance * mastery of the french language exclusion criteria: * patient under curatorship or guardianship * patient receiving french state medical aid

Keywords: juvenile idiopathic arthritis (jia) jia patients in transition towards adult ward prognosis of jia severity and structural damage in jia angiogenic and inflammatory biomarkers semaphorin (sema4a), ccn1 serum fluid synovial fluid
explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Conditions: Atrial Fibrillation

Summary: a study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). the study will compare patients assigned randomly (like flipping a coin) to either rivaroxaban or vitamin k antagonist (vka). the study will measure common medical outcomes for this type of patient such as bleeding and stroke.


Eligibility criteria:
inclusion criteria: * men or women aged \>= 18 years * hemodynamically stable nonvalvular atrial fibrillation longer than 48 hours or of unknown duration * scheduled for cardioversion (electrical or pharmacological) of nonvalvular atrial fibrillation * women of childbearing potential and men must agree to use adequate contraception when sexually active exclusion criteria: * severe, disabling stroke (modified rankin score of 4- 5, inclusive) within 3 months or any stroke within 14 days prior to randomization * transient ischemic attack within 3 days prior to randomization * acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization * acute myocardial infarction (mi) within the last 14 days prior to randomization * cardiac-related criteria: known presence of cardiac thombus or myxoma or valvular atrial fibrillation * active bleeding or high risk for bleeding contraindicating anticoagulant therapy * concomitant medications: indication for anticoagulant therapy other than atrial fibrillation, chronic aspirin therapy \> 100 mg daily or dual antiplatelet therapy, strong inhibitors of both cytochrome p450 (cyp) 3a4 and p-glycoprotein (p-gp) if used systemically * concomitant conditions: childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; hypersensitivity to investigational treatment or comparator treatment; calculated creatinine clearance (crcl) \< 30 ml/minute; hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk; any severe condition that would limit life expectancy to less than 6 months; planned invasive procedure with potential for uncontrolled bleeding; inability to take oral medication; ongoing drug addiction or alcohol abuse * any other contraindication listed in the local labeling for the comparator treatment or experimental treatment * participation in a study with an investigational drug or medical device within 30 days prior to randomization

Keywords: rivaroxaban oral anticoagulant nonvalvular atrial fibrillation cardioversion stroke transient ischemic attack thromboembolism cardiovascular event
evaluation of systemic microcirculation of patients undergoing heart valve surgery

Conditions: Microvascular Rarefaction; Heart Valve Diseases; Extracorporeal Circulation

Summary: the study aims to study the systemic microcirculation in adult patients hospitalized at a quaternary public hospital during the preoperative and immediate postoperative periods of heart valve surgery and correlations to their clinical and laboratory outcomes in the postoperative period.

despite the development of new endovascular procedures in recent years, cardiac surgery currently remains an important instrument in the management of patients with severe heart diseases, such as hemodynamically significant coronary obstructions and valve pathologies. despite the advances in the management of patients in intensive care, the postoperative period of patients undergoing cardiac surgery remains a challenge due to the intense inflammatory reaction triggered by the surgical procedure itself and exacerbated by the use of cardiopulmonary bypass (cpb), fundamental in most cardiac surgeries performed nowadays. in this context, cardiac surgery for the treatment of valve pathologies with the use of cpb is more related to unfavorable clinical outcomes in the postoperative period in relation to coronary artery bypass grafting (cabg). it is postulated, as a causal factor, the longer cpb time in valve surgeries associated with more prominent cardiac morphological changes in these patients. studies carried out in recent years in patients hospitalized in intensive care that developed a severe inflammatory reaction, either due to sepsis, surgical procedure or more recently due to the covid-19 pandemic, have shown a frequent dissociation between the hemodynamic findings measured in the icu with the data of the patients' systemic microcirculation. the use of portable microscopes has allowed the measurement of systemic microcirculation at the bedside in intensive care, enabling prompt assessment of aspects related to tissue perfusion, thus seeking to improve clinical outcomes in these patients.

Eligibility criteria:
inclusion criteria: * patients scheduled to heart valve surgery under cardiopulmonary bypass. exclusion criteria: * patients operated on for infective endocarditis

Keywords: microcirculation capillary density
antagonist protocol in poor responders

Conditions: Female Infertility Due to Diminished Ovarian Reserve

Summary: the effect of use of the growth hormone with antagonist protocol on the outcome of the ivf/icsi cycles in poor responders.

two groups of poor responder female patients planned to receive the antagonist ivf/icsi protocol are randomized to whether or not to add growth hormone to their protocol.

Eligibility criteria:
inclusion criteria: * females fulfilling the criteria of the eshre consensus 2011: * at least two of the following three features must be present: * dvanced maternal age (≥40 years) or any other risk factor for por * previous por (≤3 oocytes with a conventional stimulation protocol) * an abnormal ovarian reserve test (i.e. afc ,5-7 follicles or amh ,0.5 -1.1 ng/ml). exclusion criteria: * women who suffer from any other cause of infertility other than poor ovarian reserve * refusal of the patient to consent for using her data in the study.

Keywords: growth hormone ivf/icsi poor responder antagonist protocol
relation between mean arterial pressure and renal resistive index in the early phase of septic shock

Conditions: Septic Shock

Summary: this study evaluates if improvement of renal resistive index when mean arterial pressure increase (at 65 mmhg to 85 mmhg) in early phase of septic shock is predictive of better renal survival.

learned societes (survival sepsis campaign and esicm) are currently recommending a mean arterial pressure (map) target at 65 mmhg in septic shoc with a potential increase to 85 mmhg in patients with medical history of arterial hypertension. a high renal resistive index on the first day of septic shock was associated with acute renal failure more frequently on the 5th day. a decrease in the renal resistance index was also objectified during the increase in map. the main objective of this trial is to study the relationship between the improvement of the resistance index during a test of increase in average blood pressure during septic shock and the improvement of renal function in this interventional monocenter trial, we will measure the renal resistive index after stabilization of the map at 65 mmhg for two hours, then after 2 hours of stabilization at 85 mmhg. this part allows us to define the patients "responding" to the renal resistive index (improvement of the resitive renal index when the map increases). then, patients will be randomized into two groups : * first group with a map target at 65 mmhg * second group with a map target at 85 mmhg. there will be a stratification on the responder character to the renal resistance index. finally, we will assess renal function on the 7th day (with the assessment of serum creatinine and the change of stage of the kdigo classification)

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 ans) * admitted to the intensive care unit of angers with * arterial hypotension requiring the etablishment of catecholamines * in a context of proven or suspected sepsis, whaterver the cause of this infection. * norepinephrine dose ⩾ 0.1µg/kg/min * after 2 hours of stabilization at 65 mmhg of mean arterial pressure exclusion criteria: * pre-existing chronic renal failure (glomerular filtration rate \< 60 ml/min with mdrd) * solitary kidney (anatomical or functional) * history of united or bilateral stenosis of the renal arteries * decision to stop or limit treatment * patient with an emergency indication of renal replacement therapy (severe hyperkalemia, severe metabolical acidosis with ph \ 40 mmol/l and oliguria/anuria \> 72 h.) * pregnant, lactating or parturient woman * patient deprived of liberty by judicial or administrative decision * patient with psychiatric compulsory care * patient subject to legal protection measures

Keywords: renal resistive index mean arterial pressure
retrospective evaluation of the percentage of subjects who have reached their ldl-c objectives after treatment with inegy (study p05103)(completed)

Conditions: Primary Hypercholesterolemia

Summary: the main objective of this study is to determine the percentage of patients who met the low-density lipoprotein cholesterol (ldl-c) objective with inegy, that were not under statin monotherapy treatment.

the type of patient sampling used was consecutive patient sampling

Eligibility criteria:
inclusion criteria: * man or woman aged over 18; * patient suffering from primary hypercholesterolemia; * patient justifying treatment with inegy® (2nd intention); * patient currently treated with inegy® for at least 4 weeks; * patient with a lipid profile before treatment with inegy®, documenting a level of ldl-c exceeding the therapeutic objective under treatment with a statin as monotherapy; * patient with an evaluation of lipid disorder (eal) treated with inegy®, performed within 1 to 3 months of starting treatment. exclusion criteria: * patient not previously treated with a statin; * patient previously treated with a combination of hypolipemics; * patient treated with inegy® as first intention; * patient treated with inegy® for less than 4 weeks; * patient already included in this study.
testicular function and semen quality in male childhood and adolescent cancer survivors

Conditions: Cancer, Treatment-Related; Late Effect; Semen Analysis

Summary: cancer treatment can affect the testicular function, including sperm and hormonal functions. the aim of this study is to assess the testicular function and semen quality in young men who recover from childhood and adolescent cancer in hong kong. this can provide more information for pre-treatment counselling as well as improve post treatment survivorship care. the testicular function will be compared to aged-matched controls from men attending the family planning association for premarital check-up.

this is a cohort observational study. the target population for the trial will be men who have received chemotherapy and/ or radiotherapy for cancer diagnosed when they were \ 18 years old to 50 years old and cancer in remission for at least 2 years. the testicular function, including sperm and hormonal functions, will be compared with aged-matched controls from men attending the family planning association for premarital check-up.

Eligibility criteria:
inclusion criteria: * men who have received chemotherapy and/ or radiotherapy for cancer diagnosed when they were \< 18 years old. * \> 18 years old to 50 years old * cancer in remission for at least 2 years exclusion criteria: * unable to ejaculate by masturbation to provide semen samples * cryptorchidism, testicular cancer, history of vasectomy * on testosterone replacement therapy * refusal to join the study

Keywords: cancer treatment testicular function semen quality cancer survivors
longitudinal efficacy of dental implants in anterior areas

Conditions: Edentulous

Summary: dental implants are used in dentistry to reestablish function and appearance to areas of the mouth where natural teeth are missing. implants can be a good choice for almost all areas of the mouth except where the space left by missing teeth is too narrow. this is usually the case when front teeth are lost of have been missing since birth. the maximus dental implant is the smallest implant made, just 3mm in diameter, and is especially designed to replace missing front teeth and yet be strong enough to function as a natural tooth. this study will assess the functional success of biohorizons maximus one-piece endosseous dental implant. we hypothesize that placement of the 3mm dental implant in areas of limited tooth-to-tooth spacing will be an efficacious tooth root replacement.

when maxillary anterior (upper front)and/or mandibular incisors are congenitally missing or lost due to other causes, the space between adjacent teeth is frequently too narrow to support traditional implant therapy and patients are often advised to fill the space with conventional fixed or removable prosthetic appliances. the one-piece titanium construction of the maximus design is believed to retain optimal biomechanical stength while remaining small enough for use in anterior reconstruction thereby allowing access to spaces that were previously beyond the scope of implant dentistry.

Eligibility criteria:
inclusion criteria: * missing anterior teeth exclusion criteria: * pregnancy * cigarette smoking * diabetes mellitus * other significant medical conditions or habits likely to compromise bone healing * chronic use of medications likely to compromise bone healing

Keywords: endosseous dental implants dental aesthetics
acute and long-term outcomes of patients with acute myocardial infarction treated with pci

Conditions: Acute Myocardial Infarction; Coronary Artery Disease

Summary: randomized studies may often be burdened by the selective nature of patient inclusion thus not reflecting real-world outcomes. this is evident from the discrepancy in the mortality rates reported in major randomized trials enrolling patients with acute myocardial infarction (ami), as compared with registry data. the primary objective of this observational study is to assess short- and long-term outcomes of unselected, real-world patients presenting with ami and treated with contemporary percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction referred to catheterization laboratory for percutaneous coronary intervention exclusion criteria: * initial acute myocardial infarction diagnosis not confirmed * patients with acute myocardial infarction not undergoing invasive coronary angiography

Keywords: ami